News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting

Feb 26, 2021 8:00am EST

ADMA Biologics to Participate in Raymond James Institutional Investor Conference

Feb 22, 2021 8:00am EST

ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN

Feb 01, 2021 8:00am EST

ADMA Biologics Receives Unique Permanent J-Code for ASCENIV™

Jan 26, 2021 8:00am EST

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook

Jan 19, 2021 8:00am EST

ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™

Jan 04, 2021 8:00am EST

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

Dec 16, 2020 4:15pm EST

ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors

Dec 09, 2020 8:00am EST

ADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Maryville, TN

Dec 01, 2020 7:00am EST

ADMA Biologics to Participate in Jefferies 2020 Virtual London Healthcare Conference

Nov 10, 2020 7:00am EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...19
Next
About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

© Copyright 2021 ADMA Biologics, Inc.
Ramsey, NJ Offices 201-478-5552
Boca Raton, FL Offices 561-989-5800
info@admabio.com

Best places to work
Bio NJ

2020 Innovator Award

50 fastest companies
2019 Fast 500 Deloitte
Bio Florida

Named 2019 Company of the Year